<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740792</url>
  </required_header>
  <id_info>
    <org_study_id>MP4004</org_study_id>
    <nct_id>NCT00740792</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies</brief_title>
  <official_title>Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if two allergy medications (formulated azelastine
      and fluticasone product) are more effective than placebo or either medication alone
      (azelastine or fluticasone)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase III, randomized, double-blind, placebo-controlled, parallel-group study
      in subjects with moderate-to-severe seasonal allergic rhinitis (SAR). The study will begin
      with a 7-day, single-blind, placebo lead-in period (Day -7 to Day 1). Subjects will be
      instructed to take placebo lead-in medication twice daily (1 spray per nostril),
      approximately every 12 hours. On Day 1, subjects who satisfy the symptom severity
      requirements and continue to meet all of the study inclusion/exclusion criteria will be
      randomized in a 1:1:1:1 ratio to receive 1 spray per nostril twice daily of MP29-02,
      azelastine hydrochloride, fluticasone propionate, or placebo nasal spray.

      Efficacy will be assessed by the change from baseline in the subject-reported 12-hour
      reflective Total Nasal Symptom Score (TNSS). On Days 1 through 14, subjects will rate the
      instantaneous and reflective TNSS symptoms of sneezing, nasal congestion, runny nose, and
      nasal itching; the instantaneous and reflective total ocular symptom score (TOSS) symptoms of
      itchy eyes, watery eyes and eye redness; the symptom of postnasal drip will be rated,
      reflectively, twice daily (AM and PM) in a diary prior to the dose of study medication.
      Symptoms will be scored on a 0 to 3 scale (0 = no symptoms, 1 = mild symptoms, 2 = moderate
      symptoms, 3 = severe symptoms), such that the maximum daily symptom severity score will be 24
      for the TNSS and 18 for the TOSS. Additional secondary efficacy variables will include
      reflective individual nasal and ocular symptom scores, as well as change from Baseline to Day
      14 in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

      Subjects â‰¥ 18 years of age will complete the RQLQ on Day 1 (prior to dosing) and Day 14.
      Subjects will return to the clinic on Day 7 for an interim evaluation. After completing the
      2-week double-blind treatment period, subjects will return to the clinic on Day 14 (or at
      time of early termination) for an end-of-study evaluation. Safety and tolerability
      assessments will be made on Days 7 and 14. Tolerability will be evaluated by subject-reported
      adverse events (AEs), nasal examinations, and vital signs assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</measure>
    <time_frame>day1 to 14 days</time_frame>
    <description>change from baseline in 12-hour reflective(how you felt over the previous 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</measure>
    <time_frame>day 1 to14</time_frame>
    <description>change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative value is suggestive of improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">776</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>azelastine HCl/fluticasone propionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azelastine HCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluticasone propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine HCl/fluticasone propionate</intervention_name>
    <description>azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID</description>
    <arm_group_label>azelastine HCl/fluticasone propionate</arm_group_label>
    <other_name>MP29-02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine Hcl</intervention_name>
    <description>azelastine Hcl 548 mcg one spray per nostril BID</description>
    <arm_group_label>azelastine HCL</arm_group_label>
    <other_name>azelastine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <description>fluticasone propionate 200 mcg one spray per nostril BID</description>
    <arm_group_label>fluticasone propionate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo one spray per nostril BID</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 12 years of age and older

          -  Provide written informed consent/pediatric assent. If the subject is a minor, parent
             or legal guardian must give written informed consent

          -  Subjects must have moderate-to-severe rhinitis, defined as having one or more of the
             following:

               1. Sleep disturbance

               2. Impairment of daily activities, leisure and/or sport

               3. Impairment of school or work

               4. Troublesome symptoms

          -  Screening Visit: Have a 12-hour reflective TNSS of at least 8 of 12 and a congestion
             score of 2 or 3 on Visit 1

          -  Randomization Visit: Have a 12-hour reflective TNSS (AM or PM) of at least 8 on 3
             separate symptom assessments (one of which was within 2 days of Day 1, and can include
             the morning of Day 1) during the Lead-in Period.

          -  Randomization Visit: Have an AM or PM 12-hour reflective nasal congestion score of 2
             or 3 must have been recorded on 3 separate symptom assessments (one of which was
             within 2 days of Day 1, and can include the morning of Day 1) Randomization Visit:
             Have an instantaneous TNSS score of 8 or more at time point zero, just prior to
             beginning the onset of action assessment

          -  Have taken at least 10 doses of the lead-in medication

          -  Willing and able to comply with the study requirementsAt least a 2-year history of SAR
             during Fall allergy season

          -  The presence of IgE-mediated hypersensitivity to a local Fall pollen, confirmed by a
             positive response to skin prick within the last year. A positive response is defined
             as a wheal diameter of at least 3 mm larger than the negative control.

          -  General good health and free of disease or concomitant treatment that could interfere
             with the interpretation of the study results

          -  Subjects receiving immunotherapy injections (antigen desensitization) must be on a
             stable maintenance regimen for at least 30 days before the first study visit

          -  Subjects currently receiving sublingual immunotherapy are excluded. A 6-month washout
             period is required following the last dose of sublingual immunotherapy.

        Exclusion Criteria:

          -  On Focused Nasal Examination, the presence of any superficial and moderate nasal
             mucosal erosion, nasal mucosal ulceration, or nasal septum perforation at either the
             screening visit or randomization visit

          -  Other nasal disease(s) likely to affect deposition of intranasal medication

          -  Nasal surgery or sinus surgery within the previous year.

          -  Chronic sinusitis - more than 3 episodes per year

          -  Planned travel outside of the pollen area during the study period

          -  The use of any investigational drug within 30 days prior to Day -7.

          -  Presence of any hypersensitivity to drugs similar to azelastine hydrochloride or
             fluticasone propionate

          -  Women who are pregnant or nursing

          -  Women of childbearing potential who are not abstinent or not practicing a medically
             acceptable method of contraception*

          -  Respiratory Tract Infections within 14 days prior to Day -7

          -  Respiratory Tract Infections requiring antibiotic treatment 14 days prior to Day -7

          -  Asthma (with the exception of intermittent asthma).

          -  Significant pulmonary disease including COPD

          -  Clinically significant arrhythmia or symptomatic cardiac conditions

          -  A known history of alcohol or drug abuse within the last 2 years

          -  Existence of any surgical or medical condition or physical or laboratory findings that
             could interfere with study result interpretation.

          -  Patients with a history of Glaucoma

          -  Clinically relevant abnormal physical findings within 1 week of randomization that may
             preclude compliance with the study procedures

          -  Employees of the research center or private practice and their family members are
             excluded

          -  Subjects who participated in protocol MP4001 or MP4002
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis M Fredane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Meda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy, Asthma and Immunology Associates</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AABI Associates Medical Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Ebbling, MD Inc</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Care Center of So. Cal</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Research Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Medical Group Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bensch Research Associates</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Storms Clinical Research Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy and Asthma Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Allergy and Asthma Clinic</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze and Itch Associates</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Allergy and Asthma</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Medical Research Associates</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Reseacrh Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Asthma and Allergy Center</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Research Center</name>
      <address>
        <city>Ocean</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Center for Clinical Research</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Asthma, Sinus and Allergy Centers</name>
      <address>
        <city>Warren</city>
        <state>New Jersey</state>
        <zip>07059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Consultants of NJ/PA</name>
      <address>
        <city>Collegeville</city>
        <state>Pennsylvania</state>
        <zip>19426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Clinical Immunology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Research Associate</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy, Asthma and Urticaria of Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennesse Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Center of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jane Lee, MD, PA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Allergy and Asthma Center, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Clinical Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <results_first_submitted>May 15, 2012</results_first_submitted>
  <results_first_submitted_qc>August 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2012</results_first_posted>
  <disposition_first_submitted>June 23, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 12, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2011</disposition_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MP29-02</title>
          <description>azelastine HCl/fluticasone propionate</description>
        </group>
        <group group_id="P2">
          <title>Azelastine HCL</title>
          <description>active comparator of azelastine HCl</description>
        </group>
        <group group_id="P3">
          <title>Fluticasone Propionate</title>
          <description>active comparator of fluticasone propionate</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>placebo control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="189"/>
                <participants group_id="P4" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="186"/>
                <participants group_id="P3" count="180"/>
                <participants group_id="P4" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MP29-02</title>
          <description>azelastine HCl/fluticasone propionate</description>
        </group>
        <group group_id="B2">
          <title>Azelastine HCL</title>
          <description>active comparator of azelastine HCl</description>
        </group>
        <group group_id="B3">
          <title>Fluticasone Propionate</title>
          <description>active comparator of fluticasone propionate</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>placebo control</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="193"/>
            <count group_id="B2" value="194"/>
            <count group_id="B3" value="189"/>
            <count group_id="B4" value="200"/>
            <count group_id="B5" value="776"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="181"/>
                    <measurement group_id="B5" value="707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="14.1"/>
                    <measurement group_id="B2" value="38.2" spread="13.5"/>
                    <measurement group_id="B3" value="37.0" spread="13.6"/>
                    <measurement group_id="B4" value="37.2" spread="13.0"/>
                    <measurement group_id="B5" value="37.8" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="200"/>
                    <measurement group_id="B5" value="776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</title>
        <description>change from baseline in 12-hour reflective(how you felt over the previous 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improvement.</description>
        <time_frame>day1 to 14 days</time_frame>
        <population>Intent-to-Treat(ITT) population includes all subjects who were randomized and had at least one post baseline efficacy observation</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>azelastine HCl/fluticasone propionate</description>
          </group>
          <group group_id="O2">
            <title>Azelastine HCL</title>
            <description>active comparator of azelastine HCl</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate</title>
            <description>active comparator of fluticasone propionate</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo control</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</title>
          <description>change from baseline in 12-hour reflective(how you felt over the previous 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improvement.</description>
          <population>Intent-to-Treat(ITT) population includes all subjects who were randomized and had at least one post baseline efficacy observation</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.2"/>
                    <measurement group_id="O2" value="-4.5" spread="4.6"/>
                    <measurement group_id="O3" value="-4.6" spread="5.1"/>
                    <measurement group_id="O4" value="-3.0" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</title>
        <description>change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative value is suggestive of improvement.</description>
        <time_frame>day 1 to14</time_frame>
        <population>Intent to Treat (ITT)population includes all subjects who were randomized and had at least one post baseline efficacy observation.</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>azelastine HCl/fluticasone propionate</description>
          </group>
          <group group_id="O2">
            <title>Azelastine HCL</title>
            <description>active comparator of azelastine HCl</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate</title>
            <description>active comparator of fluticasone propionate</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo control</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</title>
          <description>change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative value is suggestive of improvement.</description>
          <population>Intent to Treat (ITT)population includes all subjects who were randomized and had at least one post baseline efficacy observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="188"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="5.3"/>
                    <measurement group_id="O2" value="-4.2" spread="4.6"/>
                    <measurement group_id="O3" value="-4.3" spread="5.2"/>
                    <measurement group_id="O4" value="-2.4" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</title>
        <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.</description>
        <time_frame>day 1 to day 14</time_frame>
        <population>Intent to Treat (ITT) population (18 yrs of age and older) who have had one post baseline efficacy observation</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>azelastine HCl/fluticasone propionate</description>
          </group>
          <group group_id="O2">
            <title>Azelastine HCL</title>
            <description>active comparator of azelastine HCl</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate</title>
            <description>active comparator of fluticasone propionate</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo control</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</title>
          <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.</description>
          <population>Intent to Treat (ITT) population (18 yrs of age and older) who have had one post baseline efficacy observation</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="169"/>
                <count group_id="O4" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.3"/>
                    <measurement group_id="O2" value="-1.4" spread="1.3"/>
                    <measurement group_id="O3" value="-1.5" spread="1.3"/>
                    <measurement group_id="O4" value="-1.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MP29-02</title>
          <description>azelastine HCl/fluticasone propionate</description>
        </group>
        <group group_id="E2">
          <title>Azelastine HCL</title>
          <description>active comparator of azelastine HCl</description>
        </group>
        <group group_id="E3">
          <title>Fluticasone Propionate</title>
          <description>active comparator of fluticasone propionate</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>placebo control</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Medra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatitis C</sub_title>
                <description>described by investigator as &quot;unlikely related to study drug&quot;</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="194"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>mucosal erosion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>nasopharyingitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>nasal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators participating in multicenter studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and Meda Pharmaceuticals.
Meda Pharmaceuticals requests that it receive copies of any intended communication reasonably in advance (at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Ginsberg,D.O.</name_or_title>
      <organization>Meda Pharmaceuticals</organization>
      <phone>7325642364</phone>
      <email>david.ginsberg@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

